Business
OWC Pharmaceutical Research Corp Receives IRB Approval to Initiate Safety Testing on its Cannabinoid-Infused Cream for Treatment of Psoriasis
OWC Pharmaceutical Research Corp Receives IRB Approval to Initiate Safety Testing on its Cannabinoid-Infused Cream for Treatment of Psoriasis.
About this update from Owc Pharmaceutical Research Corp
[{"type":"text","content":"\n\n\n\nOWC Pharmaceutical Research Corp Receives IRB Approval to Initiate Safety Testing on its Cannabinoid-Infused Cream for Treatment of Psoriasis\n\n\n\n\n\nOWC Pharmaceutical Research Corp Receives IRB Approval to Initiate Safety Testing on its Cannabinoid-Infused Cream for Treatment of Psoriasis\nProtocol Is The First Topical Medical Cannabis Treatment to be Included in NIH Registry\nPR Newswire\nPETACH TIKVA, Israel, February 27, 2017\n\n\n\nPETACH TIKVA, Israel, February 27, 2017 /PRNewswire/ --\n\nOWC Pharmaceutical Research Corp. (OTCQB: OWCP), (\"OWC\" or the \"Company\"), an Israeli-based developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today announced it has received Institutional Review Board (IRB) approval to conduct safety testing on its proprietary topical crème compound for the treatment of psoriasis and related skin conditions. The approval follows the Company's February 1, 2017 8K filing announcing an extension to the size and scope of its efficacy study on the same compound, which began in November 2106.\n\n     (Logo: http://mma.prnewswire.com/media/458036/OWC_Logo.jpg )\n\n\nThe IRB approved study encompasses the cream itself, as a delivery mechanism, as well as the proprietary psoriasis formulation, and is the first to formally make such claims with the NIH Registry. The double-blind study, which will be conducted on healthy volunteers at one of Israel's leading academic hospitals, is designed to demonstrate the safety of the formulation in treating psoriasis on human skin tissue. Administrators began soliciting for study participants as soon as approval was received.\n\nDr. Yehuda Baruch, the Company's Director of Research and Regulatory Affairs, commented on the announcement, \"This approval is a significant milestone for OWC, where our mission is to bring the same rigorous approach common to traditional pharmaceutical development to the medical cannabis field. As we reported earlier this year, the results of our efficacy studies were so encouraging that management decided it was in our interest to extend the size and scope of the study to check the biological markers that had been generated to date, among other things. \"\n\nDr. Baruch went on to say, \"With each study we conduct, the ability of our formulation to provi...